MYRIAD GENETICS INC. - COMMON STOCK

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

16 May 2024 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MYRIAD GENETICS INC. - COMMON STOCK

10 May 2024 08:45:09 By NetDania Notify

NetDania - New 12 months High: MYRIAD GENETICS INC. - COMMON STOCK

09 May 2024 08:49:28 By NetDania Notify

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

07 May 2024 08:00:00 By Nasdaq GlobeNewswire

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

30 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

17 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

16 Apr 2024 08:15:00 By Nasdaq GlobeNewswire

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

21 Mar 2024 20:40:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

20 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

27 Feb 2024 15:05:01 By Nasdaq GlobeNewswire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

27 Feb 2024 08:15:00 By Nasdaq GlobeNewswire

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

21 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

15 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

01 Feb 2024 08:25:00 By Nasdaq GlobeNewswire

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

30 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

18 Jan 2024 17:10:00 By Nasdaq GlobeNewswire

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

09 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 15:05:00 By Nasdaq GlobeNewswire